Orion Corporation: Organising meeting of the Board of Directors

In its organising meeting, the Board of Directors of Orion Corporation, which was elected today by the Annual General Meeting of the Shareholders, has elected Timo Maasilta as Vice Chairman.

The compositions of the Board committees were decided to be as follows:

Remuneration Committee:
Hannu Syrjänen, Chairman
Mikael Silvennoinen

Heikki Westerlund
Jukka Ylppö

Audit Committee:
Heikki Westerlund, Chairman
Timo Maasilta
Eija Ronkainen
Mikael Silvennoinen

R&D Committee:
Sirpa Jalkanen, Chairman
Timo Maasilta
Eija Ronkainen
Mikael Silvennoinen
Hannu Syrjänen
Heikki Westerlund
Jukka Ylppö

The members to the Nomination Committee were elected on 29 October 2015 as stated in the stock exchange release on the same day.

The Board of Directors has assessed the independence of its members and concluded that all the members are independent of the company and its significant shareholders.

Orion Corporation

Timo Lappalainen                   Olli Huotari
President and CEO                 Senior VP, Corporate Functions

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2015 amounted to EUR 1,016 million and the company had about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.